Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment

NCT01067053 is registered in ClinicalTrials.gov with Grupo Espanol Multidisciplinario del Cancer Digestivo as lead sponsor.

NCT NCT01067053
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01067053 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non Randomized Phase II Trial to Assess Efficacy and Safety of Bevacizumab, Capecitabine and Oxaliplatin as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polychemotherapy Treatment
Lead sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2009
Completion date
March 31, 2014
Enrollment
69 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer